Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the ...

A Friedreich ataxia specialist discusses how the typical clinical presentation of Friedreich's Ataxia includes early onset with symptoms such as ataxia and sensory loss, while also examining the ...

Friedreich’s ataxia is a progressive neuromuscular disease that causes uncoordinated movement, muscle weakness, balance problems, impaired speech, and frequently, heart abnormalities.

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Larimar Therapeutics (NASDAQ:LRMR) was started at outperform by Wedbush based on the company’s drug candidate nonlabofusp for ...

Some investors might want to combine high yield with growth-like exposure. Check out two picks with attractive yields, while ...

Acting Manhattan Supreme Court Justice Anar Rathod Patel last week denied a motion to dismiss from defendants Reata and Biogen, finding that fact questions remained.

Sexual dimorphism is identified in a mouse model of Friedreich’s ataxia, with males exhibiting a worse cardiac phenotype, low survival rate, as well as kidney and reproductive organ deficiencies.